Text this: Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

   _____    ______   __   __    _____     ______  
  / ___//  /_   _//  \ \\/ //  |  ___||  /_   _// 
  \___ \\   -| ||-    \   //   | ||__      | ||   
  /    //   _| ||_    / . \\   | ||__     _| ||   
 /____//   /_____//  /_//\_\\  |_____||  /__//    
`-----`    `-----`   `-`  --`  `-----`   `--`